EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Selpercatinib in Treatment of Advanced Medullary Thyroid Cancer: Effectiveness and Side Effects – A Case Report of 2 Patients during 60 Months of Therapy

Luciano Severgnini, Bernd Hartmann, Doz Thomas Winder, Theresia Lang, Andreas Volgger, Magdalena Benda, Patrick Reimann

Case Reports in Oncology · 22.08.2026 · 19 (1) · 1512-1523

DOI: 10.1159/cro/abzag009 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Oncology, online erschienen am 22.08.2026. Verfasst von Luciano Severgnini und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Internal Medicine II: Oncology and Hematology, Gastroenterology and Infective Disease, Landeskrankenhaus of Feldkirch, Feldkirch, Austri…. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Medullary thyroid carcinoma (MTC) is a rare, but aggressive tumor that accounts for 4% of thyroid carcinomas. A mutation in the proto-oncogene RET has been shown to occur in ca. 70% of those neoplasia. Selpercatinib is a newly approved drug that specifically targets the RET-kinase and demonstrated a very high efficacy in reducing the tumor activity and in progression-free survival in patients with an advanced metastatic disease [1]. Case Presentation: In accordance with the approval of the FDA, we started a treatment with selpercatinib on 2 patients with advanced metastatic MTC with an established RET mutation. They received selpercatinib 160 mg bidaily, and we observed the patients for 60 months. We observed a very good metabolic and serological response to the treatment with a decrease in the tumor marker of 99.8% and 98.5% and stable imaging. Hypertension grade II, hypotension grade I, proteinuria grade I, hyperphosphatemia grade I, and hypocalcemia grade II were the low-grade side effects that we observed during these 60 months of therapy.

Conclusion

Selpercatinib proved to be a good antineoplastic drug for patients with RET-mutated, advanced, and inoperable MTC.

Schlagwörter

Stichwörter der Autor:innen

MetastasisRET mutationSelpercatinibThyroid carcinomaTyrosine kinase inhibitor

Autor:innen und Institutionen

  • Institute of Internal Medicine II: Oncology and Hematology, Gastroenterology and Infective Disease, Landeskrankenhaus of Feldkirch, Feldkirch, Austria.
  • University in Principality of Liechtenstein (UFL), Triesen, Liechtenstein.
  • University and Oncological Center of Zurich, Swiss Tumor Immunology Institute, Zurich, Switzerland.

Zitieren

APA

Severgnini, L., Hartmann, B., Winder, D. T., Lang, T., Volgger, A., Benda, M., & Reimann, P. (2026). Selpercatinib in Treatment of Advanced Medullary Thyroid Cancer: Effectiveness and Side Effects – A Case Report of 2 Patients during 60 Months of Therapy. Case Reports in Oncology, 19(1), 1512-1523. https://doi.org/10.1159/cro/abzag009

Vancouver

Severgnini L, Hartmann B, Winder DT, Lang T, Volgger A, Benda M, et al. Selpercatinib in Treatment of Advanced Medullary Thyroid Cancer: Effectiveness and Side Effects – A Case Report of 2 Patients during 60 Months of Therapy. Case Reports in Oncology. 2026;19(1):1512-1523. doi:10.1159/cro/abzag009

BibTeX
@article{Severgnini2026,
  author = {Severgnini, Luciano and Hartmann, Bernd and Winder, Doz Thomas and Lang, Theresia and Volgger, Andreas and Benda, Magdalena and Reimann, Patrick},
  title = {Selpercatinib in Treatment of Advanced Medullary Thyroid Cancer: Effectiveness and Side Effects – A Case Report of 2 Patients during 60 Months of Therapy},
  journal = {Case Reports in Oncology},
  year = {2026},
  volume = {19},
  number = {1},
  pages = {1512--1523},
  doi = {10.1159/cro/abzag009}
}
Kostenlos starten →